Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
Open Access
- 5 July 2012
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 23 (8) , 2204-2205
Abstract
Individual cases of prolonged complete response (CR) of HER2-positive metastatic breast cancer (MBC) have been reported following treatment with trastuzumab/chemotherapy, but the frequency of durable remission is unknown [1, 2].Keywords
This publication has 4 references indexed in Scilit:
- Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortThe Lancet, 2010
- When Should Trastuzumab be Stopped after Achieving Complete Response in Her2-Positive Metastatic Breast Cancer Patients?Tumori Journal, 2007
- A patient with breast cancer with hepatic metastases and a complete response to herceptin as monotherapyClinical and Translational Oncology, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000